PhysicianWednesday, December 4, 2019, 8:00 am – 5:30 pm
Thursday, December 5, 2019, 8:00 am – 12:15 pm

Where:
Rancho Bernardo Inn
17550 Bernardo Oaks Drive
San Diego, CA 92128

Financial Disclosure Information

AAAP's interprofessional continuing education program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. During the planning process, anyone that is involved in the content is required to disclose to AAAP and our learners any real or potential conflict of interest related to the educational activity. Please note the following disclosures: John Mariani, MD, Kevin Sevarino, MD, PhD, Richard Rosenthal, MD, Edward Nunes, MD, Frances Levin, MD, Eric Collins, MD, and Nicole Potito have no relevant financial relationships with an ACCME-defined commercial interest to disclose.

Jill Williams, MD receives grant support from Pfizer. Larissa Mooney, MD served on an advisory board for Alkermes. Kevin Gray, MD provided consultation to Pfizer.

Who Should Attend?
This intensive two-day, 12 hour course is designed for physicians, nurse practitioners and PA’s who have a foundation in prescribing medication for patients with substance use disorders but would like a deeper understanding of these pharmacologies. The Advanced Addiction Psychopharmacology Course will be approached as a didactic lecture with equal time for peer discussion and questions and answers.

This Advanced Course will be held simultaneously to AAAP’s Addictions and Their Treatment (AATT) course prior to AAAP’s Annual Meeting. Please note that there is a slight overlap with the AATT course and the Annual Meeting.

Joint Accreditation

View Continuing Education Credits

Educational Objectives

This course is designed for learners with a foundational knowledge of addiction psychiatry will who wish to receive a more in-depth educational training in addiction psychopharmacology.

After participating in this course, learners should be able to:

  • Describe how to use methadone, buprenorphine and naltrexone in clinical practice for the treatment of opioid use disorders.
  • Describe medication treatments for alcohol use disorders.
  • Determine when to use varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorder.
  • Discuss new evidence-based medication treatments for cocaine and methamphetamine use disorder.
  • Discuss new evidence-based medication treatments for cannabis use disorder.
  • Discuss medication approaches for the treatment of sedative-hypnotic use disorder.
  • List evidence-based options for anti-depressant and anti-anxiety pharmacotherapy when treating patients with a co-occurring substance use disorder.
  • Discuss evidence-based pharmacotherapy for treatment of ADHD with co-occurring substance use disorders.
  • Discuss the pharmacotherapy of bipolar disorder in patients with co-occurring substance use disorder.